靶向抗癌新突破:BCL-XL降解剂DT2216首次人体试验结果公布

动脉网
Nov 17, 2025

靶向抗癌新药BCL-XL降解剂DT2216的首次人体I期临床试验结果公布,该药物通过结合BCL-XL并招募VHL E3泛素连接酶,选择性地降解癌细胞中的BCL-XL,减少对血小板的毒性。这项多中心、开放标签、剂量递增的I期试验纳入了20例经多线治疗失败的晚期实体瘤患者,剂量从0.04 mg/kg逐步递增至0.4 mg/kg,旨在评估其安全性、药代动力学与初步疗效。DT2216为克服传统BCL-XL...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10